Evidence map›Paper›PMID 31113383›Full record

ArticleBMC genomics2019

Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomics.

Azam Yazdani, Akram Yazdani, Sarah H Elsea, Daniel J Schaid, Michael R Kosorok, Gita Dangol, Ahmad Samiei

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 2 countries.

Azam YazdaniBoston University, Boston, MA, 02118, USA. a.mandana.yazdani@gmail.com.
Akram YazdaniDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, 10029, USA.
Sarah H ElseaDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Daniel J SchaidDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, 55905, USA.
Michael R KosorokDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Gita DangolHealth Science Center, The University of Texas MD Anderson Cancer Center, Austin, TX, 77030, USA.
Ahmad SamieiHasso Plattner Institute, 14482, Potsdam, Germany.
Baylor College of Medicine · USBoston University · USHasso Plattner Institute · DEIcahn School of Medicine at Mount Sinai · USMayo Clinic · USThe University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · US

Funding

Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIDIAN, MARIE, KOSOROK, MICHAEL R · 2010 to 2019
$21.3M
Quantitative Methods for Genetic EpidemiologyR01GM065450 · NIGMS · MAYO CLINIC ROCHESTER · PI SCHAID, DANIEL J. · 2002 to 2020
$5.6M
Quantitative Methods for Genetic EpidemiologyR35GM140487 · NIGMS · MAYO CLINIC ROCHESTER · PI SCHAID, DANIEL J. · 2021 to 2025
$1.9M
NCI NIH HHS P01 CA142538NIGMS NIH HHS R01 GM065450NIGMS NIH HHS R35 GM140487NIH HHS GM065450
6 · The paper itself

Abstract

backgroundMany genome-wide association studies have detected genomic regions associated with traits, yet understanding the functional causes of association often remains elusive. Utilizing systems approaches and focusing on intermediate molecular phenotypes might facilitate biologic understanding.

resultsThe availability of exome sequencing of two populations of African-Americans and European-Americans from the Atherosclerosis Risk in Communities study allowed us to investigate the effects of annotated loss-of-function (LoF) mutations on 122 serum metabolites. To assess the findings, we built metabolomic causal networks for each population separately and utilized structural equation modeling. We then validated our findings with a set of independent samples. By use of methods based on concepts of Mendelian randomization of genetic variants, we showed that some of the affected metabolites are risk predictors in the causal pathway of disease. For example, LoF mutations in the gene KIAA1755 were identified to elevate the levels of eicosapentaenoate (p-value = 5E-14), an essential fatty acid clinically identified to increase essential hypertension. We showed that this gene is in the pathway to triglycerides, where both triglycerides and essential hypertension are risk factors of metabolomic disorder and heart attack. We also identified that the gene CLDN17, harboring loss-of-function mutations, had pleiotropic actions on metabolites from amino acid and lipid pathways.

conclusionUsing systems biology approaches for the analysis of metabolomics and genetic data, we integrated several biological processes, which lead to findings that may functionally connect genetic variants with complex diseases.

Indexed as

Genetic PleiotropyGenome, HumanMetabolomicsMutationAdaptor Proteins, Signal TransducingAlgorithmsBlack or African AmericanHumansMetabolomeWhite PeopleAdaptor Proteins, Signal TransducingBNIPL protein, humanCausal network in observational studyGenome analysisInstrumental variableLoss of functionMendelian randomization principlesStructural equation modelingThe G-DAG algorithmUnderlying metabolomic relationship

Identifiers

PMID31113383
PMCPMC6528192
OpenAlexW2941107942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.